: Kadcyla. ?  »
|
-

I.V

Powder For Concentrate For Solution For Infusion

KADCYLA, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: • Received prior therapy for metastatic disease, or • Developed disease recurrence during or within six months of completing adjuvant therapy.

151 63 33939 00

Hoffmann La Roche, Switzerland

03/2014 - 12/2015

.
, .
.
/
Trastuzumab emtansine 20 MG/ML
Vial 15 ml glass type i x 100 MG 36
Vial 20 ml glass type i x 160 MG 36

*

*

 

.

? !
 »
 
" !
 

. :  »
169
-